Geode Capital Management
GANX icon

Geode Capital Management’s Gain Therapeutics GANX Stock Holding History

Geode Capital Management’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$869K Buy
447,342
+49,400
+12% +$107K ﹤0.01% 3402
2025
Q4 		$1.28M Buy
397,942
+53,796
+16% +$144K ﹤0.01% 3305
2025
Q3 		$609K Buy
344,146
+53,684
+18% +$90.6K ﹤0.01% 3542
2025
Q2 		$523K Buy
290,462
+8,251
+3% +$15.3K ﹤0.01% 3538
2025
Q1 		$539K Buy
282,211
+14,790
+6% +$32.8K ﹤0.01% 3512
2024
Q4 		$578K Sell
267,421
-4,551
-2% -$9.13K ﹤0.01% 3558
2024
Q3 		$484K Buy
271,972
+88,236
+48% +$111K ﹤0.01% 3588
2024
Q2 		$235K Buy
183,736
+6,645
+4% +$17.3K ﹤0.01% 3857
2024
Q1 		$668K Buy
177,091
+25,615
+17% +$106K ﹤0.01% 3511
2023
Q4 		$495K Hold
151,476
– – ﹤0.01% 3614
2023
Q3 		$489K Buy
151,476
+12,755
+9% +$48.4K ﹤0.01% 3611
2023
Q2 		$621K Buy
138,721
+44,514
+47% +$217K ﹤0.01% 3560
2023
Q1 		$454K Buy
94,207
+4,093
+5% +$16.7K ﹤0.01% 3677
2022
Q4 		$282K Buy
90,114
+2,147
+2% +$6.71K ﹤0.01% 3922
2022
Q3 		$286K Buy
87,967
+62,149
+241% +$234K ﹤0.01% 4013
2022
Q2 		$92K Buy
25,818
+190
+0.7% +$655 ﹤0.01% 4623
2022
Q1 		$104K Buy
25,628
+5,572
+28% +$23.3K ﹤0.01% 4647
2021
Q4 		$107K Buy
+20,056
New +$138K ﹤0.01% 4708

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management's GANX Position: Q1 2026 in Review

Geode Capital Management increased its Gain Therapeutics (GANX) stake by 12% in Q1 2026, buying an estimated $107K and bringing the position to 447,342 shares worth $869K. The position accounts for ﹤0.01% of the portfolio, ranked #3402.

Geode Capital Management first reported a position in GANX in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.28M in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Geode Capital Management held 447,342 shares of Gain Therapeutics worth $869K as of Q1 2026.
  • Geode Capital Management bought 49,400 Gain Therapeutics shares in Q1 2026, an estimated $107K.
  • Gain Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3402 holding.
  • Geode Capital Management first reported a position in Gain Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Geode Capital Management's Gain Therapeutics position peaked at $1.28M in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.